Newborn screening looks for select genetic, metabolic, and endocrine conditions, including galactosemia, G6PD deficiency, and phenylketonuria. Routine panels generally don’t screen for hepatitis, though separate steps help protect infants from hepatitis B passed from mother to baby.

Multiple Choice

Which of the following is NOT included in the newborn screening diseases?

Newborn screening is a public health program aimed at detecting certain genetic, endocrine, and metabolic disorders in newborns during the first few days of life. The primary purpose of this screening is to identify conditions that can be treated early to prevent serious health issues or developmental delays. Galactosemia, G6PD (Glucose-6-Phosphate Dehydrogenase deficiency), and Phenylketonuria (PKU) are all included in standard newborn screening panels, as these conditions can lead to severe complications if not detected and managed early. For instance, galactosemia can result in liver damage and cognitive impairment, G6PD deficiency can cause hemolytic anemia, and untreated phenylketonuria can lead to intellectual disability. On the other hand, hepatitis is generally not a part of routine newborn screening. Although hepatitis B and C can be transmitted from mother to child and may lead to severe health problems, infants are typically vaccinated against hepatitis B shortly after birth rather than screened for the infection during the newborn screening process. Therefore, identifying hepatitis infections does not fall under the direct scope of newborn screening in the same way as the specific metabolic and genetic disorders listed. Understanding the rationale behind the inclusion and exclusion of diseases in newborn

Newborn Screening: Finding Hidden Conditions Early

A newborn may look healthy and still have a condition that needs attention. That’s why newborn screening matters. In the first days of life, a small blood sample can help identify certain genetic, metabolic, and hormone-related disorders before symptoms appear. Early detection gives families and health teams time to act—often before a condition causes lasting harm.

Newborn screening is a public health program, not a complete check of every possible illness. The conditions included depend on the country or region, and screening methods can change as medical knowledge and technology improve. Still, many programs look for disorders such as galactosemia, glucose-6-phosphate dehydrogenase deficiency, and phenylketonuria. Hepatitis, by contrast, is generally handled through separate maternal and infant care rather than as one of the disorders on a routine newborn blood-spot panel.

That distinction can seem surprising. Hepatitis can affect infants, so why isn’t it usually grouped with these other conditions? The answer lies in what newborn screening is designed to detect—and how each condition is best found and managed.

A small sample with a big job

Newborn screening usually begins with a few drops of blood collected from a baby’s heel. The sample is placed on a special card and sent to a laboratory. Depending on the local program, the screening may also include a hearing check and a measurement of oxygen levels.

The blood test looks for signs linked to specific disorders. It does not always diagnose a condition on its own. Instead, a result outside the expected range may signal that follow-up tests are needed. This is an important point for families: a “positive” screening result is not always a confirmed diagnosis. It is a reason to investigate promptly.

Timing matters. Many screened disorders are difficult to spot by appearance alone during the first days of life. A baby can seem well while a harmful substance builds up in the body, or while a missing enzyme begins to affect normal development. Screening can bring that hidden risk into view before clear symptoms emerge.

Why these disorders make the list

Programs choose conditions based on factors such as how serious they can be, whether early treatment can help, and whether a reliable screening method is available. The details vary by location, but the goal is broadly the same: find conditions for which early information can change a child’s care.

Galactosemia

Galactosemia affects how the body processes galactose, a sugar found in milk and other foods. In a common form, the body lacks enough of an enzyme needed to break galactose down. Without early care, harmful substances can build up and cause serious problems, including liver damage, infection, and difficulties with growth and development.

Newborn screening can flag signs of the disorder soon after birth. If follow-up confirms the diagnosis, a care team can guide the family on limiting galactose in the baby’s diet. That early change can reduce the risk of severe complications. It’s a striking example of how a simple lab result can shape daily care from the beginning.

G6PD deficiency

Glucose-6-phosphate dehydrogenase, or G6PD, is an enzyme that helps protect red blood cells. When a person has G6PD deficiency, certain infections, medicines, or foods can trigger the breakdown of red blood cells. This is called hemolysis. The resulting anemia can range from mild to severe, and newborns may also develop high levels of bilirubin, which can cause jaundice.

Screening helps identify babies who may need closer monitoring and guidance about triggers. G6PD deficiency is inherited, and its frequency varies among populations. That makes local screening policies and family history relevant, though a family may not know of any relatives with the condition.

Phenylketonuria

Phenylketonuria, often shortened to PKU, affects the body’s ability to process phenylalanine, an amino acid found in protein. If phenylalanine builds up to high levels, it can harm the brain and affect development.

A baby with PKU may appear well at birth. Screening can detect the problem before signs become obvious, allowing a specialist team to guide nutrition and monitor the child’s health. Ongoing care may involve a carefully managed diet and regular checks of phenylalanine levels. It’s not a one-time issue, but early detection gives families a clearer path forward.

So where does hepatitis fit?

Hepatitis is inflammation of the liver. Some forms are caused by viruses, including hepatitis B and hepatitis C. These infections can pass from a pregnant parent to a baby, so they deserve serious attention. But they are not generally part of the routine newborn blood-spot screening panel.

Instead, hepatitis is usually addressed through other steps. Screening during pregnancy can identify infection in the parent. If hepatitis B is present, the newborn may receive a hepatitis B vaccine and, in certain circumstances, hepatitis B immune globulin shortly after birth. These measures help lower the chance of infection being passed to the infant. Follow-up may also be needed to check whether the prevention measures worked.

Hepatitis C is managed differently, and infants born to a parent with hepatitis C may need follow-up testing at an appropriate age. The details depend on local guidance and the family’s circumstances.

So, “not on the newborn screening panel” does not mean “not important” or “never checked.” It means the condition is addressed through a different route. Newborn screening focuses largely on selected disorders that can be detected through specific early tests and may benefit from timely intervention. Maternal infection screening, vaccination, preventive treatment, and follow-up each serve a different role.

Screening is a system, not a single test

It helps to think of newborn screening as one part of a wider safety net. The blood-spot sample can identify certain metabolic or inherited conditions. A hearing screen checks for hearing loss, while a pulse-oximetry test can help detect some serious heart conditions. Maternal health checks and newborn vaccinations add other layers of protection.

No screening program catches every condition. Nor does every program include the same list. A country may add or remove conditions as evidence changes, laboratory capacity grows, and public health priorities shift. Families should follow the guidance given by their local health service, since names, timelines, and follow-up steps can differ.

A result that needs follow-up can feel unsettling. That reaction is understandable. But screening is designed to flag possible concerns early; it is not the final word about a child’s health. The next step may be a repeat sample, a more specific blood test, or an appointment with a specialist. Clear communication matters here, because families need to know what the result means and what will happen next.

Why early detection matters

The main value of newborn screening is time. Some conditions can cause harm before a family has any reason to suspect them. Early detection can make it possible to change a baby’s diet, monitor for complications, begin treatment, or arrange follow-up while the child is still well.

Galactosemia, G6PD deficiency, and PKU illustrate different reasons a condition may be included in a screening program. One affects sugar processing, another can make red blood cells vulnerable, and a third disrupts the handling of an amino acid. They are not the same illness, but each can benefit from being recognized early.

Hepatitis remains important, too—it is simply addressed through different public health tools. That distinction helps explain newborn screening’s purpose: it is not a broad search for every infection or health concern. It is a targeted program, built around conditions that can be identified early and managed in ways that improve a child’s outlook.